Study #2020-1155
A PHASE IIA STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND EFFICACY OF APG-115 AS A SINGLE AGENT OR IN COMBINATION WITH APG-2575 IN SUBJECTS WITH RELAPSED/REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA (R/R T-PLL)
MD Anderson Study Status
Enrolling
Treatment Agent
APG-115, APG-2575
Description
This is a multi-center, open-label, phase IIa study to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL. The study consists of two parts. A total of 24-36 T-PLL patients will be enrolled.
Information and next steps
Disease:
T-Prolymphocytic Leukemia
Study phase:
II
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.